β-Alanine, an important amino acid product, is witnessing a steady and structurally optimized market growth thanks to its wide applications in sports nutrition, feed, pharmaceuticals and other fields. The industry is generally featured by "expanding demand, technological upgrading and concentrated competition pattern", promising a bright long-term outlook.
In terms of market scale, China's β-alanine industry continues to expand. The market size reached approximately 1.38 billion yuan in 2024, maintaining a growth rate of over 10% in 2025. The compound annual growth rate (CAGR) of the industry is expected to stay at 7%–10% from 2026 to 2030, with the domestic market size exceeding 1.8 billion yuan by 2030. The global market is also growing steadily, with a size of about $96.3 million in 2024, and a CAGR of over 4.3% projected from 2025 to 2034.
The application end presents a pattern of "multi-point support and key breakthroughs". Feed additives account for the largest share of total consumption at 42%, used to improve muscle buffering capacity and promote growth in livestock, with stable demand driven by large-scale aquaculture. Vitamin B5 synthesis takes up 27.5%, as a key intermediate benefiting from the steady expansion of the calcium pantothenate market. Sports nutrition and functional foods have become the strongest growth engine, with consumption in this sector surging by 217% in 2026 compared with 2020, representing an annual growth rate of 19.3%. β-alanine can increase muscle carnosine concentration and delay fatigue. After being approved as a food nutrition fortifier in 2025, its compliant application in China has accelerated, with rising penetration among fitness enthusiasts. Demand in pharmaceutical intermediates, cosmetics and other sectors is also gradually releasing, marked by a notable increase in clinical trial applications for new drugs containing β-alanine structures.
Technologically, the industry is undergoing a green transformation. The traditional acrylonitrile-based chemical process accounts for over 85% of domestic total capacity; though mature, it suffers from high pollution and energy consumption. Leading enterprises such as Huheng Pharmaceutical have made breakthroughs in biological enzymatic synthesis, enabling production under normal temperature and pressure with zero high-salt wastewater discharge and product purity exceeding 99%, while costs keep declining. Amid stricter environmental policies, the share of enzymatic capacity will rise from 10% in 2025 to over 20% by 2030, driving the industry toward low-carbon and high-efficiency development.
In terms of competition, the domestic market is gradually becoming more concentrated. The CR4 reached about 42.3% and CR8 58.7% in 2024, with CR4 expected to surpass 55% by 2030 as leading players accelerate integration of small and medium-sized capacities with advantages in technology, production and compliance. China has become the world's largest producer and exporter of β-alanine, accounting for over 65% of global total capacity. Leading enterprises including Huheng Pharmaceutical and NHU are enhancing their global competitiveness with green processes and high-purity products.
In the long run, the market outlook for β-alanine remains positive, though challenges such as acrylonitrile price fluctuations, stricter environmental regulations and higher standards for food and pharmaceutical grades require attention. Overall, driven by the upgrading of health consumption, the boom in sports nutrition and the transformation of green manufacturing, the β-alanine industry will maintain high-quality growth, and enterprises with technological and scale advantages will fully benefit from the industry's dividends.